Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01018095 · ClinicalTrials.gov registry record · Phase 4
Trichomonas Vaginalis Recurrence Among HIV+ Women
A Phase 4 study, sponsored by Tulane University Health Sciences Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 270
- Enrollment target
NCT01018095: Completed Phase 4 study, sponsored by Tulane University Health Sciences Center.
NCT01018095 is a Phase 4 study that has completed, run by Tulane University Health Sciences Center. The registered enrollment target is 270 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01018095, a Phase 4 study, has completed, sponsored by Tulane University Health Sciences Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 270 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the 2 gram single dose of metronidazole is as effective as the 7 day 500 mg BID dose for treatment of Trichomonas vaginalis (TV) among HIV-infected women.
Primary Outcome
At the participants' test of cure (TOC) visits they were screened for Trichomonas vaginalis using (InPouch) culture. Presence of parasite will yield a culture positive result.
Interventions
- DRUG Metronidazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2005-05 |
| Est. Completion | 2009-08 |
| Phase | Phase 4 |
What the finished NCT01018095 record still lists
NCT01018095 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 1 intervention - of which Metronidazole is the first listed.
NCT01018095 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01018095 about?
NCT01018095 is a clinical study titled "Trichomonas Vaginalis Recurrence Among HIV+ Women". The purpose of this study is to determine if the 2 gram single dose of metronidazole is as effective as the 7 day 500 mg BID dose for treatment of Trichomonas vaginalis (TV) among HIV-infected women.
What is the current status of trial NCT01018095?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 270 participants. The study started on 2005-05. Estimated completion is 2009-08.
What interventions are being tested in trial NCT01018095?
The interventions under investigation include: Metronidazole (DRUG).
Who is sponsoring clinical trial NCT01018095?
This trial is sponsored by Tulane University Health Sciences Center, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01018095's enrollment target sits among peer trials
270 318th of 2000 higher than 1,682 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- NCT04372485 · 270 participants · NA
Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents
- NCT04528446 · 270 participants
The Impact of Glomerular Disorders on Bone Quality and Strength
- NCT05215327 · 270 participants · Phase 2
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia